Revenue
2022
2023
2024
2025
PepGen Inc. (PEPG)
Price$3.11Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $71.0M | $76.5M | $68.1M | $54.1M | $19.0M |
| Operating expenses | $93.6M | $97.7M | $84.8M | $68.3M | $27.1M |
| Operating income | −$93.6M | −$97.7M | −$84.8M | −$68.3M | −$27.1M |
| EBITDA | −$92.2M | −$96.2M | −$83.6M | −$67.8M | −$26.9M |
| Net income | −$89.7M | −$90.0M | −$78.6M | −$69.1M | −$27.3M |
| Basic EPSper basic share | -$2.12 | -$2.85 | -$3.30 | -$4.42 | -$30.27 |
| Diluted EPSper diluted share | -$2.12 | -$2.85 | -$3.30 | -$4.42 | -$30.27 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 20.06M |
Oxford Science Enterprises plc | 4.96M |
Commodore Capital LP | 4.48M |
VIKING GLOBAL INVESTORS LP | 3.48M |
Laurion Capital Management LP | 2.75M |
ADAR1 Capital Management, LLC | 2.59M |
Vivo Capital, LLC | 2.33M |
VANGUARD CAPITAL MANAGEMENT LLC | 1.94M |
MILLENNIUM MANAGEMENT LLC | 1.79M |
RENAISSANCE TECHNOLOGIES LLC | 1.52M |
BlackRock, Inc. | 1.3M |
MARSHALL WACE, LLP | 866.99K |
GSA CAPITAL PARTNERS LLP | 852.85K |
CITADEL ADVISORS LLC | 658.38K |
AWM Investment Company, Inc. | 600K |
MONIMUS CAPITAL MANAGEMENT, LP | 587.69K |
Squarepoint Ops LLC | 529.08K |
GEODE CAPITAL MANAGEMENT, LLC | 523.47K |
Creek Drive Management Group LLC | 450K |
Ikarian Capital, LLC | 447.17K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2026Form 4 | Kasraian KasraChief Technical Officer | SellCommon Stock | 1.2K | $1.41 | $1.7K | 50.1K |
| Mar 4, 2026Form 4 | STRECK PAULEVP, Head of R&D | SellCommon Stock | 47 | $6.29 | $295.63 | 76.2K |
| Mar 4, 2026Form 4 | STRECK PAULEVP, Head of R&D | SellCommon Stock | 1.8K | $6.23 | $11.4K | 76.3K |
| Mar 4, 2026Form 4 | Donnelly NoelChief Financial Officer | SellCommon Stock | 52 | $6.33 | $329.16 | 111.6K |
| Mar 4, 2026Form 4 | Donnelly NoelChief Financial Officer | SellCommon Stock | 2.0K | $6.23 | $12.7K | 111.7K |
Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
